Locoregional treatments for triple-negative breast cancer. by Eiermann, W, Vallis, K

“…The absence of drug-targetable receptors in triple-negative breast cancer (TNBC) makes the use of targeted systemic therapy inappropriate for this breast cancer subgroup. …”

What is the risk of cardiac morbidity with adjuvant radiotherapy for breast cancer? by Vallis, K

Postoperative radiotherapy for breast cancer: growing evidence for an impact on survival. by Vallis, K, Tannock, I

Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. by Wang, J, Chen, P, Su, Z, Vallis, K, Sandhu, J, Cameron, R, Hendler, A, Reilly, R

“…A method is described to amplify the delivery of 111In to human breast cancer cells utilizing a novel human serum albumin-human EGF (HSA-hEGF) bioconjugate substituted preferentially in the HSA domain with multiple DTPA metal chelators for 111In. 111In-DTPA-HSA-hEGF exhibited a lower receptor-binding affinity than 111In-DTPA-hEGF but was rapidly and specifically bound, internalized and translocated to the nucleus in EGFR-positive MDA-MB-468 breast cancer cells. 111In-DTPA-HSA-hEGF was cytotoxic in vitro mainly through the emission of short-range Auger electrons and partially through the effects of the hEGF moiety to MDA-MB-468 cells overexpressing EGFR (1-2 x 10(6) receptors/cell) but not towards MCF-7 breast cancer cells with a 100-fold lower level of EGFR on their surface. …”

111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. by Reilly, R, Kiarash, R, Cameron, R, Porlier, N, Sandhu, J, Hill, R, Vallis, K, Hendler, A, Gariépy, J

“…The internalization of 111In-DTPA-hEGF by MDA-MB-468 breast cancer cells (1.3x10(6) EGFRs/cell) was determined by displacement of surface-bound radioactivity by an acid wash. …”

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. by Reilly, R, Kiarash, R, Sandhu, J, Lee, Y, Cameron, R, Hendler, A, Vallis, K, Gariépy, J

“…Receptor binding assays were conducted in vitro against MDA-MB-468 human breast cancer cells. Biodistribution and tumor imaging studies were conducted after intravenous injection of the radiopharmaceuticals in athymic mice bearing subcutaneous MCF-7, MDA-MB-231, or MDA-MB-468 human breast cancer xenografts or in severe combined immunodeficiency mice implanted with a breast cancer metastasis (JW-97 cells). …”

Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer. by Cornelissen, B, Able, S, Kartsonaki, C, Kersemans, V, Allen, P, Cavallo, F, Cazier, J, Iezzi, M, Knight, J, Muschel, R, Smart, S, Vallis, K

In-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR by Reilly, R, Kiarash, R, Cameron, R, Porlier, N, Sandhu, J, Hill, R, Vallis, K, Hendler, A, Gariepy, J

Moleculary targeted auger electron radiation therapy for breast cancer: A clinical trial. by Vallis, K, Reilly, R, Scollard, D, Chen, P, Wang, J, Petronis, J

Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. by Vallis, K, Pintilie, M, Chong, N, Holowaty, E, Douglas, P, Kirkbride, P, Wielgosz, A

“… PURPOSE: To assess the risk of fatal and nonfatal myocardial infarction (MI) after breast-conserving surgery (BCS) and radiation therapy (RT) for left-sided breast cancer. …”

Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series. by Paszat, L, Sutradhar, R, Grunfeld, E, Gainford, C, Benk, V, Bondy, S, Coyle, D, Holloway, C, Sawka, C, Shumak, R, Vallis, K, van Walraven, C

“… GOAL: To ascertain outcomes of surveillance mammography (SM) following treatment of early stage unilateral primary breast cancer (PBC) in a population based case series. …”

Breast cancer in women < or = 35 years: review of 1002 cases from a single institution. by Chan, A, Pintilie, M, Vallis, K, Girourd, C, Goss, P

“…BACKGROUND: Early-onset breast cancer may differ with respect to etiology, clinical features and outcome compared with breast cancer in older women. …”

A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. by Paszat, L, Vallis, K, Benk, V, Groome, P, Mackillop, W, Wielgosz, A

“… OBJECTIVE: To describe the risk of acute myocardial infarction (AMI) after radiation therapy (RT) for breast cancer (BrCa) in an exposed population. METHODS: We identified and validated cases of AMI (vAMI), by electrocardiographic or enzyme criteria, among all 6680 women who received post-operative RT following lumpectomy or mastectomy, within 12 months following diagnosis of BrCa between 1982 and 1988 in Ontario, Canada. …”

DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers. by Kotsopoulos, J, Chen, Z, Vallis, K, Poll, A, Ainsworth, P, Narod, SA

“…An impaired cellular response to DNA damage is a plausible mechanism whereby BRCA1 mutation carriers are at increased risk of breast cancer. Hence, an individual's capacity to repair DNA may serve as a useful biomarker of breast cancer risk. …”

A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer by Vallis, K, Reilly, R, Scollard, D, Merante, P, Freeman, M, Lockwood, G, Sabate, K, Brade, A

In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy. by Cornelissen, B, Kersemans, V, McLarty, K, Tran, L, Vallis, K, Reilly, R

“…Trastuzumab-induced p27(kip1) up-regulation was assessed in a panel of breast cancer cell lines by Western blot analysis. …”

Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. by Cai, Z, Chen, Z, Bailey, K, Scollard, D, Reilly, R, Vallis, K

“…The purpose of this study was to investigate the relationship between EGFR expression, DNA damage, and cytotoxicity in cells exposed to 111In-DTPA-hEGF. METHODS: Breast cancer cell lines with a range of EGFR expression levels were exposed to 111In-DTPA-hEGF or gamma-radiation. …”

3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation by Skaripa-Koukelli, I, Hauton, D, Walsby-Tickle, J, Thomas, E, Owen, J, Lakshminarayanan, A, Able, S, McCullagh, J, Carlisle, R, Vallis, K

“…<br><strong>Background<br></strong> Triple negative breast cancer (TNBC) poses a serious clinical challenge as it is an aggressive form of the disease that lacks estrogen receptor, progesterone receptor, and ERBB2 (formerly HER2) gene amplification, which limits the treatment options. …”

Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells. by Chen, P, Mrkobrada, M, Vallis, K, Cameron, R, Sandhu, J, Hendler, A, Reilly, R

“…The antiproliferative effects of (111)In-DTPA-hEGF on breast cancer cells expressing high levels of EGFR were compared with those of chemotherapeutic agents or gamma-radiation. …”

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. by Costantini, D, Bateman, K, McLarty, K, Vallis, K, Reilly, R

“…The cytotoxicity of (111)In-NLS-trastuzumab on breast cancer cells was directly correlated with the HER2 expression densities of the cells. …”